期刊文献+

晚期糖基化终末产物抑制剂在心血管疾病中的研究进展

下载PDF
导出
摘要 晚期糖基化终末产物(AGEs)通过各种机制参与心血管疾病的发生发展,AGEs抑制剂可通过减轻AGEs负荷而成为心血管病治疗的药物。本文分类概述了AGEs抑制剂的作用机制及临床应用,综合评价各类AGEs抑制剂的作用特点,便于其临床的合理应用。
作者 袁音 朱鹏立
出处 《心血管康复医学杂志》 CAS 2012年第3期332-334,共3页 Chinese Journal of Cardiovascular Rehabilitation Medicine
基金 福建省自然科学基金(2010J1127)
  • 相关文献

参考文献17

  • 1Ko SY,Lin YP,Lin YS. Advanced glycation end products enhance amyloid precursor protein expression by inducing reactive oxygen species[J].Free Radical Biology and Medicine,2010,(03):474-480.
  • 2Coker LH,Wagenknecht LE. Advanced glycation end products,diabetes,and the brain[J].Neurology,2011,(14):1326-1327.
  • 3Chang JB,Chu NF,Syu JT. Advanced glycation end products (AGEs) in relation to atherosclerotic lipid profiles in middleaged and elderly diabetic patients[J].LIPIDS IN HEALTH AND DISEASE,2011,(01):228.
  • 4Yah SF,Ramasamy R,Schmidt AM. The receptor for advanced glycation endproducts (RAGE) and cardiovascular disease[J].Expert Reviews In Molecular Medicine,2009.e9.
  • 5林虹,朱鹏立.晚期糖基化终末产物及其受体在原发性高血压中的作用机制[J].国际老年医学杂志,2010,31(4):165-170. 被引量:8
  • 6Kilhovd BK,Juutilainen A,Lehto S. High serum levels of advanced glycation end products predict increased coronary heart disease mortality in nondiabetic women but not in nondiabetic men:a population-based 18-year follow-up study[J].Arteriosclerosis,Thrombosis,and Vascular Biology,2005,(04):815-820.
  • 7Prévost G,Bulckaen H,Gaxatte C. Structural modifications in the arterial wall during physiological aging and as a results of diabetes mellitus in a mouse model:are the changes comparable[J].Diabetes & Metabolism,2011,(02):106-111.
  • 8Peng X,Ma J,Chen F. Naturally occurring inhibitors against the formation of advanced glycation end-products[J].Food Funct,2011,(06):289-301.
  • 9Little WC,Zile MR,Kitzman DW. The effect of alagebrium chloride (ALT-711),a novel glucose cross link breaker,in the treatment of elderly patients with diastolic heart failure[J].Journal of Cardiac Failure,2005,(03):191-195.doi:10.1016/j.cardfail.2004.09.010.
  • 10Voziyan PA,Hudson BG. Pyridoxamine as a multifunctional pharmaceutical:targeting pathogenic glycation and oxidative damage[J].Cellular and Molecular Life Sciences,2005,(15):1671-1681.

二级参考文献43

  • 1Singh R, Barden A, Mori T, et al. Advanced glycation end - products: a review [ J ]. Diabetologia, 2001, 44: 129-146.
  • 2Schmidt AM, Vianna M, Gerlaeh M, et al. Isolation and eharacterisation of two binding proteins for advanced glycosylation endproduets from bovine lung which are present on the endothelial cell surface [J]. Biol Chem, 1992, 267: 14987-14997.
  • 3Li J, Schmidl AM. Charaeterization and functional analysis of the prnmoter of RAGE: the receptor for advanced glycation end products [ J ]. Biol Chem, 1997, 272: 16498-16506.
  • 4Diego G, Colomba F, Enzo E. Soluble receptor for advanced glyeation end products: from disease marker to potential therapeutic target [ J ]. Curr Med Chem, 2006, 13: 1971 - 1978.
  • 5Sudesh V, Vicki G, Pawan S. Role of advanced glycation end products in hypertension and athcrosclero sis: therapeutic implication [ J ]. Cell Biochem Biophy, 2007, 49: 48-63.
  • 6Morgan P, Dean R, Davies M. lnaetlvation of celluar enzymes by carbonyls and protein - bound glycation/ glycoxidation products [ J ]. Arch Brochem Biophy, 2002, 403:259 -269.
  • 7Wang X, Desai K, Chang T, et al. Vascular methylglyoxal metabolism and the development of hypertension [J]. Hypertension, 2005, 16: 173-179.
  • 8Wu L, Juurlink BH. Increased methylglyoxal and oxidative stress in hypertensive rat vascular smooth muscle cells [J]. Hypertension, 2002, 39: 809-814.
  • 9Alp NJ, Channon KM. Regulation of endnthchal nitric oxide synthase by tetrahydrobiopetin in vascular disease [J]. Arterioscler Thromb Vasc Biol, 2004, 24:413- 420.
  • 10Bucala R, Tracey KJ, Cerami A. Advanced glycosylation products quench nitric oxide and mediate defective endotheliumdependent vasodilation in experimental diabetes [J]. Clin Invest, 1991, 87: 432- 438.

共引文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部